Results 41 to 50 of about 19,727 (209)

Blocking Zika virus vertical transmission. [PDF]

, 2018
The outbreak of the Zika virus (ZIKV) has been associated with increased incidence of congenital malformations. Although recent efforts have focused on vaccine development, treatments for infected individuals are needed urgently. Sofosbuvir (SOF), an FDA-
Beltrão-Braga, Patricia CB, Corbett, Kevin D, Cugola, Fernanda R, Fernandes, Isabella R, Herai, Roberto H, Huang, Chun-Teng, Kolar, Matthew J, Macia, Angela, Mesci, Pinar, Momper, Jeremiah D, Montefusco, Sandro, Moore, Spencer M, Muotri, Alysson R, Pinto, Antonella, Rosenberg, Scott C, Russo, Fabiele B, Saghatelian, Alan, Sheets, Nicholas, Shiryaev, Sergey A, Shresta, Sujan, Siqueira-Neto, Jair L, Suarez, Nicole A, Tejwani, Leon, Terskikh, Alexey V   +23 more
core   +2 more sources

Diminishing Use of Liver Biopsy among Liver Transplant Recipients for Hepatitis C. [PDF]

, 2017
Background and Aims: Hepatitis C virus (HCV) cirrhosis is the leading indication for liver transplantation in the United States and recurrent HCV following liver transplantation is a major cause of allograft loss and mortality.
Aby, Elizabeth, Agopian, Vatche, Busuttil, Ronald W, French, Samuel W, Grotts, Jonathan F, Jimenez, Melissa A, Saab, Sammy   +6 more
core   +1 more source

Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C

Journal of Virus Eradication, 2016
Objectives: Novel treatments for hepatitis C demonstrate high cure rates, but current high prices can be a barrier to rapid global treatment scale-up. Generic competition can rapidly lower drug prices.
Andrew Hill, Bryony Simmons, Dzintars Gotham, Joseph Fortunak   +3 more
doaj   +1 more source

A Cross-Sectional Study Comparing the Frequency of Drug Interactions After Adding Simeprevir- or Sofosbuvir-Containing Therapy to Medication Profiles of Hepatitis C Monoinfected Patients. [PDF]

, 2015
INTRODUCTION:This study compares the expected occurrence of contraindicated drug-drug interactions (XDDIs) when simeprevir (SIM)- or sofosbuvir (SOF)-containing therapy is added to medication profiles of patients with hepatitis C (HCV) monoinfection to ...
Bliss, Steven, Davis, Melissa, Koroglu, Arden, McNutt, Louise-Anne, Miller, Christopher, Nasiri, Mona, Patel, Nimish   +6 more
core   +1 more source

DIRECT ACTING ANTIVIRAL TREATMENT FOR PATIENTS WITH END STAGE KIDNEY DISEASE WITH ACUTE HCV INFECTION

Mediterranean Journal of Hematology and Infectious Diseases, 2019
Background: Hepatitis C virus (HCV) infection is a public health problem. Such an infection is prevalent and aggressive in patients with end-stage kidney disease (ESKD).
Nawfal R Hussein, Zana Saleem, Kais Abd
doaj   +1 more source

The evaluation of liver fibrosis regression in chronic hepatitis C patients after the treatment with direct-acting antiviral agents – A review of the literature [PDF]

, 2019
The second-generation of direct-acting antiviral agents are the current treatment for chronic viral hepatitis C infection. To evaluate the regression of liver fibrosis in patients receiving this therapy, liver biopsy remains the most accurate method, but
Alexescu, Teodora G, Cibu, Bianca A, Ciulei, George, Coste, Sorina C, Cozma, Angela, Mureșan, Flaviu, Negrean, Vasile, Orasan, Olga H, Ovidiu, Fabian, Pfingstgraf, Iulia O, Popovici, Ionela E, Tarmure, Simina F, Taut, Adela V. S   +12 more
core   +3 more sources

The deleterious effects of sofosbuvir and ribavirin (antiviral drugs against hepatitis C virus) on different body systems in male albino rats regarding reproductive, hematological, biochemical, hepatic, and renal profiles and histopathological changes

Scientific Reports
Sofosbuvir is one of the crucial drugs used in the treatment of chronic hepatitis C virus (HCV) in adults and children with compensated liver disease, including cirrhosis. It may be used alone or with other drugs.
Rana A. Ali, Eatemad A. Awadalla, Yahia A. Amin, Samer S. Fouad, Maha Abd-El Baki Ahmed, Mohammed H. Hassan, Emaad Abdel-Kahaar, Rehab H. Abdel-Aziz   +7 more
doaj   +1 more source

New-Onset Diabetes Mellitus With Exposure to Ledipasvir and Sofosbuvir

Journal of Investigative Medicine High Impact Case Reports, 2015
The combination therapy of ledipasvir/sofosbuvir was approved by the Food and Drug Administration in 2014 for the treatment of chronic hepatitis C. Although hyperglycemia is not well known to occur with its use, we present 2 cases of new-onset diabetes ...
Resmi Premji MD, Nira Roopnarinesingh MD, Nazia Qazi MD, Eric S Nylen MD   +3 more
doaj   +1 more source

Era of direct acting anti-viral agents for the treatment of hepatitis C. [PDF]

, 2018
Hepatitis C infection is universal and the most common indication of liver transplantation in the United States. The period of less effective interferon therapy with intolerable side effects has gone.
Ahmed, Monjur
core   +1 more source

Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis [PDF]

, 2016
UNLABELLED: Prisoners have a high prevalence of hepatitis C virus (HCV), but case-finding may not have been cost-effective because treatment often exceeded average prison stay combined with a lack of continuity of care. We assessed the cost-effectiveness
Brew, Iain F., Hickman, Mathew, Hutchinson, Sharon J., Irving, William L., Mandal, Sema, Martin, Natasha K., Miners, Alec, O'Moore, Eamonn, Saksena, Sushma, Vickerman, Peter, Williamson, Joan   +10 more
core   +3 more sources